Drug Shortage Report for HEPARIN SODIUM INJECTION, USP
| Report ID | 148577 |
| Drug Identification Number | 02264315 |
| Brand name | HEPARIN SODIUM INJECTION, USP |
| Common or Proper name | Heparin Sodium Injection, USP 1 000 USP units/mL MD Vial 1 mL |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | HEPARIN SODIUM |
| Strength(s) | 1000UNIT |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS |
| Packaging size | 1 mL |
| ATC code | B01AB |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2021-11-30 |
| Actual start date | 2021-11-30 |
| Estimated end date | 2022-01-10 |
| Actual end date | 2022-01-18 |
| Shortage status | Resolved |
| Updated date | 2022-01-19 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to further production delays we will be extending the backorder on our Heparin Sodium Injection, USP 1 000 USP units/mL MD Vial 1 mL until January 10, 2022. Effective December 10, 2021, our Heparin Sodium Injection, USP 1 000 USP units/mL MD Vial 10 mL format will be available for substitution. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v11 | 2022-01-19 | English | Compare |
| v10 | 2022-01-17 | French | Compare |
| v9 | 2022-01-17 | English | Compare |
| v8 | 2021-12-03 | French | Compare |
| v7 | 2021-12-03 | English | Compare |
| v6 | 2021-12-01 | French | Compare |
| v5 | 2021-12-01 | English | Compare |
| v4 | 2021-12-01 | French | Compare |
| v3 | 2021-11-01 | English | Compare |
| v2 | 2021-11-01 | French | Compare |
| v1 | 2021-11-01 | English | Compare |
Showing 1 to 11 of 11